Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 1965 of 8975 results

  1. Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]

    Awaiting development Reference number: GID-TA11931 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]

    Awaiting development Reference number: GID-TA11935 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Miniature lens system implantation for advanced age-related macular degeneration

    Awaiting development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  6. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  8. Pain management (young people and adults)

    Awaiting development Reference number: GID-QS10093 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Sleep disordered breathing

    Awaiting development Reference number: GID-QS10096 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Abdominal aortic aneurysm

    Awaiting development Reference number: GID-QS10035 Expected publication date: TBC

    Quality standard
    Awaiting development